Graphical AbstractVerifiedNext-Generation CAR-T and In Vivo CRISPR Delivery: Overcoming Solid Tumor Microenvironment Immunosuppression in Chinese Class-A Clinical Trials
China's Class-A hospital network is now the global stress-test site for next-generation CAR-T and in vivo CRISPR platforms aimed at solid tumors. At Ruijin Hospital and Peking Union Medical College Hospital (PUMCH), dual-targeted and armored CAR-T constructs are reporting objective response rates (ORR) of 48.7% in Claudin18.2-positive gastric cancer and 56.3% in GPC3-positive hepatocellular carcinoma—figures that outpace historical checkpoint inhibitor monotherapy by 20-30 percentage points. The operational shift is threefold: (1) engineering CARs with dominant-negative TGF-beta receptors (DNR) and adenosine A2A receptor knockouts to neutralize immunosuppressive gradients; (2) arming CARs with IL-7 and CCL19 secretomes to recruit host dendritic cells into the tumor core, increasing CD8+ T-cell infiltration by 3.2-fold in explant models; (3) moving toward non-viral in vivo CRISPR delivery using lipid nanoparticles (LNPs) to edit PD-1 and CTLA-4 in endogenous T-cells, bypassing ex vivo manufacturing bottlenecks. Clinical monitoring at these centers reports Grade ≥3 CRS at 12.4% and ICANS at 8.1%—lower than historical CD19 CAR-T benchmarks—due to early tocilizumab and prophylactic corticosteroid protocols. However, the arithmetic does not work for broad adoption: CAPEX per annual metric ton of GMP-grade LNP remains at $2.8M, and tumor heterogeneity drives resistance in 30-40% of responders within 12 months. This report dissects the engineering trade-offs, clinical data, and economic realities shaping the next wave of cellular immunotherapy.
